title: [Assay of methylated gene RARbeta2 in circulating DNA of blood from patients with lung cancer as a potential prognostic marker].
abstract: Blood-based methylated DNA gene RARbeta2 in circulating plasma (cir DNA) and one associated with blood cell surface were assayed in patients with non small cell lung cancer before and after combined treatment. The levels in both appeared to be significantly higher than in healthy subjects. Enhanced levels prior to treatment were associated with greater advancement of the disease and unfavorable prognosis (overall survival). After two courses of neoadjuvant therapy plus surgery methylation indices fell down to match those in healthy subjects. Our data may be instrumental in working out additional criteria to be used in diagnosis, prognosis and follow-up of patients with non small cell lung cancer.
authors: A A
authors: AA
authors: Ponomareva
authors: E Iu
authors: EIu
authors: Rykova
authors: N V
authors: NV
authors: Cherdyntseva
authors: T E
authors: TE
authors: Skvortsova
authors: A Iu
authors: AIu
authors: Dobrodeev
authors: N V
authors: NV
authors: Litviakov
authors: A A
authors: AA
authors: Zav'ialov
authors: S A
authors: SA
authors: Tuzikov
authors: V V
authors: VV
authors: Vlasov
authors: P P
authors: PP
authors: Laktionov
mesh_terms: D000328:Adult; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000235:genetics* / Q000628:therapy; D004273:DNA, Neoplasm / Q000097:blood*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000235:genetics* / Q000628:therapy; D008297:Male; D008745:Methylation; D008875:Middle Aged; D011379:Prognosis; D011401:Promoter Regions, Genetic; D018168:Receptors, Retinoic Acid / Q000235:genetics*; D012307:Risk Factors
chemical_list: D004273:DNA, Neoplasm; D018168:Receptors, Retinoic Acid; C540966:retinoic acid receptor, beta2, human